Camrelizumab (SHR-1210) is a human IgG4-kappa monoclonal antibody with high affinity directed against PD-1, binding PD-1 with an affinity of up to 3 nM and inhibiting PD-1/PD-L1 with an IC50 of 0.70 nM. Camrelizumab exhibits anti-tumor activity and is well tolerated in cancers, including NSC-LC, ESCC, Hodgkins lymphoma, and advanced HCC.
Molecular Weight:
143.7 kDa
Purity:
98.60%
CAS Number:
[1798286-48-2]
Target:
PD-1/PD-L1
T37535
* VAT and and shipping costs not included. Errors and price changes excepted
